UNIVERSITAT KONSTANZ;THURGAUISCHE STIFTUNG FA¼R WISSENSCHAFT UND FORSCHUNG
发明人:
MARCUS GROETTRUP,PETER OEHLSCHLAEGER
申请号：
GB0921088
公开号：
GB2484058A
申请日:
2009.12.01
申请国别(地区):
GB
年份:
2012
代理人:
摘要：
An agent for the treatment and prevention of prostate cancer comprises a recombinant prostate acid phosphatase (PAP) nucleic acid. The recombinant, optimized PAP genes are useful as DNA vaccines against prostate cancer. Preferably the PAP DNA vaccine is a modified form of the PAP cDNA sequence, which includes one or more of the following modifications； deletion of the signal sequence, codon optimisation for humans, linkage with an SV40 enhancer, linkage with a Kozak sequence, and/or linkage with a J-domain. The PAP gene may be a mouse gene, and may comprise the PAP A, PAP B or PAP C gene.
